Gastroenterology

Ugras describes recent evolutions in EoE, including new FDA-approved therapies, updated clinical guidelines, and better understanding of its pathophysiology.

Brogan explains how to navigate the complexities of the Crohn’s disease treatment landscape and why patients need to be included in the decision making process.

McCarty explains progress made with new screening options but emphasizes ongoing barriers hindering screening goals and how they need to be addressed.

Skarbinski explains challenges providers face when managing refractory GERD and common misconceptions about its diagnosis and treatment.

Stewart explains recent advances in eosinophilic gastrointestinal diseases and breaks down new ACG EoE guidelines.

Check out expert perspectives on unmet needs and advances in gastroparesis and new research on C. diff, IBS, and more in this August 2025 recap.

The 9-week intervention targeting positive psychological wellbeing in IBS was feasible, well-accepted, and linked to improvements in IBS-related outcomes.

A trio of experts reflect on unmet needs in gastroparesis, from diagnosis to treatment, and discuss advances that could shape the future of care.

Targeted C.difficile screening and prophylaxis focused on high-risk immunocompromised patients was linked to reductions in hospital-onset infection.

C difficile carriers had greater baseline hazard for hospital-onset infection than non-carriers, with risk not significantly affected by antibiotic exposure.

An audio recap of the top 5 stories in healthcare news from the week of 08/03-08/09.

Stay updated with the latest healthcare breakthroughs, including an FDA approval and new clinical trial data, in this week's essential news roundup.

Findings from the IBS in America Survey suggest IBS symptoms disrupt patients’ productivity and personal activities 19 days each month.

From clinical trial updates in IBD to novel research about IBS and other disorders of gut brain interaction, catch up on the latest headlines in GI.

Findings confirm a significant post-pandemic rise in disorders of gut-brain interaction, including IBS and functional dyspepsia.

Bercik reviews study findings suggesting gluten restriction is not necessary for most patients with IBS, citing its apparent lack of impact on symptoms.

Patients and clinicians perceived a gap that largely didn't exist in views on diet's role in IBD.

Sands describes the current landscape of Crohn’s disease therapies and reviews GALAXI 2 and 3 data supporting guselkumab’s role in evolving care paradigms.

Anti-TNF therapies show strong 3-year durability in pediatric IBD, with new clinical markers helping predict early nonresponse in Crohn’s disease and UC/IBD-unclassified cases.

A study investigating frequently used treatments, mean duration from first symptom to index date, and disease phenotypes found most cases are mild to moderate.

A new study highlights stress, concussion, and other early-life factors as key contributors to pediatric pain-predominant DGBIs.

Positive topline results showed obefazimod met its primary endpoint for clinical remission at week 8 in the 50 mg dose cohort in ABECT-1 and ABECT-2.

Study findings showed IBS patients with self-perceived gluten sensitivity reacted similarly to gluten, wheat, and sham challenges.

The most effective FMT strategy involved giving FMT as multiple-dose capsules or colonoscopy after an extended period of antibiotic pretreatment.

Patients who adhered to a strict 12-week low FODMAP diet saw improvements in fatigue, anxiety, and depression, and performed better on an attention test.